Vion Presents Promising Initial Data From Lung Cancer Trial
Posted on: Friday, 27 October 2006, 21:00 CDT
Vion Pharmaceutical has presented data from its lead anticancer drug Cloretazine as a single agent in a phase II trial in patients with relapsed or refractory small cell lung cancer.
The phase II trial evaluates Cloretazine in two separate subpopulations of small cell lung cancer, sensitive relapsed disease and refractory disease. Sensitive relapsed disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy.
Of the patients on the sensitive relapsed arm, there has been an overall response rate of 32%. Of those patients with refractory disease treated with Cloretazine, one patient achieved a partial response and three patients have demonstrated stable disease.
"Cloretazine has impressive activity to date in the second-line small cell lung cancer setting. These data provide a strong rationale for further study of this drug," commented Dr Anthony Greco, director of the Sarah Cannon Research Institute.
Small cell lung cancer accounts for up to 20% of all lung cancer cases according to the American Cancer Society. It is an aggressive cancer that has a poor survival rate.
Source: Datamonitor
Related Articles
- Allos Therapeutics Announces Interim Data From Phase 1 Study of PDX in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- StemLifeLine Introduces First Service Allowing IVF Patients to Develop Personal Stem Cell Lines
- Millennium Files sNDA for VELCADE(R) (Bortezomib) for Injection in Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Merck Announces Pivotal Phase IIb Study Results of the Company's Investigational HDAC Inhibitor ZOLINZA(TM) (Vorinostat) in Patients With Advanced, Refractory Cutaneous T-Cell Lymphoma (CTCL)
- VELCADE(R) (Bortezomib) for Injection May Offer New Standard of Care in Relapsed/Refractory Mantle Cell Lymphoma
- New Cell Line Helps Prostate Cancer Study
- Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
- Asterand to Distribute University of Michigan Breast Cancer (SUM) Cell Lines
- FDA Grants VELCADE(R) (Bortezomib) for Injection Fast Track Status for Relapsed and Refractory Mantle Cell Lymphoma
- New Stem Cell Lines to Be Made Available
 |
 |
User Comments (0)
RSS Feeds